Our new on-line tool simscells.com
The DIALCAT project is a collaborative project of industrial research, experimental development and innovation in the Community RIS3CAT “TEC-SALUT”, managed by ACCIÓ and co-financed by the European Regional Development Fund (ERDF). The project is based on epidemiological data confirming that patients with diabetes have 2 to 3 times higher prevalence of severe cognitive impairment and […]
The MICROBIOTA project is a collaborative project of industrial research, experimental development and innovation in the Community RIS3CAT “INNOAPAT”, managed by ACCIÓ and co-financed by the European Regional Development Fund (ERDF).
Validating the effect of a drug or vaccine is crucial to know its real power. Anaxomics participated in the SysMalVac research project, integrating data from experimental assays and identifying biomarkers of immune protection to malaria.
Last 16-17 December, Anaxomics hosted in Barcelona the last meeting of the European research project CombiMS, aimed at fighting multiple sclerosis by finding new combination therapies and biomarkers, partly through the application of systems biology, the core competency of Anaxomics. In this meeting, the team discussed the progress that each partner has achieved, as well […]
Knowing personal skin-age related genetic polymorphisms is crucial to choose the best product for each costumer. Read our next post explaining how we created a line of genetically personalized cosmetics.
On September 17-18 2014, Anaxomics hosted the 24M-month meeting of the FP7 funded European project VISION at its headquarters in Barcelona, Spain. About thirty scientists from the five partner institutions and SMEs of the consortium participated in the meeting, which marked important milestones in the development of the project. Eduardo Soriano from CSIC, the scientific […]
The Anaxomics team published an article on the application of systems biology to the selection of nutraceutical treatments for NAFLD in the NUTRAfoods journal. This article describes the use of our proprietary TPMS technology to identify the best nutraceuticals for the treatment of NAFLD and to describe their action on the disease. You can read the […]
The transition from preclinical to clinical research marks a critical turning point in the drug development process. Unfortunately, despite high R&D expenditures, attrition rates remain high, with most drugs failing due to safety and efficacy issues. Discover the underlying causes of this long-standing problem and how systems biology can address it.
Are you involved in early drug development and need to compare the efficacy of your compound with other drug competitors? Do you want to test your hypotheses in human-physiology based models? Discover the Anaxomics customized in silico services for highlighting strengths of early-stage developmental compounds.
Anaxomics’s systems biology-based drug repositioning combines the best from the heuristic and rational drug repositioning approaches, while overcoming their limitations. We offer both companies and academic and clinic researchers this 75 % success rate technology, which has let us patent several drugs and drug combinations.